Related references
Note: Only part of the references are listed.Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO)
Jun Iwamoto et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2016)
Zoledronate Attenuates Accumulation of DNA Damage in Mesenchymal Stem Cells and Protects Their Function
Juhi Misra et al.
STEM CELLS (2016)
Preadmission Bisphosphonate and Mortality in Critically Ill Patients
Paul Lee et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Comparison of the prognosis of bisphosphonate-related osteonecrosis of the jaw caused by oral and intravenous bisphosphonates
T. Shintani et al.
INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2015)
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
R. Coleman et al.
LANCET (2015)
Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus
Aliya A. Khan et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
NOD/SCID-GAMMA Mice Are an Ideal Strain to Assess the Efficacy of Therapeutic Agents Used in the Treatment of Myeloma Bone Disease
Michelle A. Lawson et al.
PLOS ONE (2015)
Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research
Elizabeth Shane et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study
A. Sakai et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Equilibrium-dependent bisphosphonate interaction with crystalline bone mineral explains anti-resorptive pharmacokinetics and prevalence of osteonecrosis of the jaw in rats
Akishige Hokugo et al.
BONE (2013)
Standardized Nomenclature, Symbols, and Units for Bone Histomorphometry: A 2012 Update of the Report of the ASBMR Histomorphometry Nomenclature Committee
David W. Dempster et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Bisphosphonate Use Is Associated With Reduced Risk of Myocardial Infarction in Patients With Rheumatoid Arthritis
Frederick Wolfe et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates
Naomi Gronich et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Intratibial Injection of Human Multiple Myeloma Cells in NOD/SCID IL-2Rγ(Null) Mice Mimics Human Myeloma and Serves as a Valuable Tool for the Development of Anticancer Strategies
Julia Schueler et al.
PLOS ONE (2013)
Selective Purging of Human Multiple Myeloma Cells from Autologous Stem Cell Transplantation Grafts using Oncolytic Myxoma Virus
Eric Bartee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy
Stephanie T. Chang et al.
BONE (2012)
Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate-Danish National Register Based Cohort Study
M. Pazianas et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Atypical Subtrochanteric Femoral Fractures in Patients with Skeletal Malignant Involvement Treated with Intravenous Bisphosphonates
Mark E. Puhaindran et al.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2011)
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial
Gareth J. Morgan et al.
LANCET ONCOLOGY (2011)
Oral bisphosphonates are associated with reduced mortality after hip fracture
L. A. Beaupre et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Differences Between Bisphosphonates in Binding Affinities for Hydroxyapatite
M. A. Lawson et al.
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS (2010)
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption
R.C. Mühlbauer et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Potential Mediators of the Mortality Reduction With Zoledronic Acid After Hip Fracture
Cathleen S. Colon-Emeric et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
TGF-β Inhibition Restores Terminal Osteoblast Differentiation to Suppress Myeloma Growth
Kyoko Takeuchi et al.
PLOS ONE (2010)
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: Time-dependent inhibition of human farnesyl pyrophosphate synthase
James E. Dunford et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
R. G. G. Russell et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy
Chih-Tai Leu et al.
BONE (2006)
Transforming growth factor-beta in osteolytic breast cancer bone metastases
TA Guise et al.
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2003)
Highly potent geminal bisphosphonates.: From pamidronate disodium (Aredia) to zoledronic acid (Zometa)
L Widler et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Share Paper
